Pharmaceuticals

Omnicell, Inc. Signs Agreement to Acquire Germany-based Pharmacy Automation Provider, MACH4 Pharma Systems

MOUNTAIN VIEW, Calif., Feb. 27, 2015 /PRNewswire/ -- Omnicell, Inc . (OMCL), a leading provider of medication and supply management solutions to healthcare systems and pharmacies, today announced that it has signed an agreement to purchase MACH4 Pharma Systems, based in ...

2015-02-27 11:25 2493

MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I

HAYWARD, Calif. and SHANGHAI, Feb. 25, 2015 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has received the approval from the U.S. Food and Drug Administration (FDA) to initiate Phase 2 clini...

2015-02-25 21:00 2009

Takeda Regroups Singapore Operations in New, Expanded Office

SINGAPORE and OSAKA, Japan, Feb. 25, 2015 /PRNewswire/ -- Takeda Pharmaceutical Company Limited today announced the inauguration of its new office in Biopolis, Singapore. The expanded space will host key Takeda functions -- its Emerging Markets Business Unit headquarters, Takeda Development Center...

2015-02-25 10:00 1884

Merck Serono and Sysmex Inostics Announce First Liquid Biopsy RAS Biomarker Testing Center Opens: Important Milestone for mCRC Patients

DARMSTADT, Germany and BARCELONA, Spain, Feb. 20, 2015 /PRNewswire/ -- * Vall d'Hebron, Spain: first hospital to use liquid biopsy RAS biomarker testing technology  * Leading research center will use technology to evolve understanding of who will benefit most from targeted treatment to impro...

2015-02-20 18:30 2519

China Cord Blood Corporation to Report Third Quarter and First Nine Months of Fiscal 2015 Financial Results

HONG KONG, Feb. 17, 2015 /PRNewswire/ -- China Cord Blood Corporation (NYSE: CO) (the "Company") today announced its plan to release its unaudited financial results for the third quarter and first nine months of fiscal 2015 onWednesday, February 25, 2015, after market close in the US. The C...

2015-02-17 20:00 2063

Merck Strengthens Presence as Leading Oncology Company by Taking Full Promotional Responsibility for Erbitux in Japan

BUDAPEST, Hungary, Feb. 13, 2015 /PRNewswire/ -- Merck, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials, today announced that Merck and Bristol-Myers Squibb have agreed to transfer full responsibility for the promotion of E...

2015-02-13 21:01 2786

AMRI Realigns Global Operations to Enhance Continuous Supply Chain for Customers

ALBANY, N.Y., Feb. 13, 2015 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it has implemented several changes to further optimize global business operations in order to enhance continuity from early development through to commercial supply and accelerate the company's global growth obje...

2015-02-13 05:00 2891

BioFire Defense, a bioMerieux Company, Receives Prestigious Frost & Sullivan's 2014 Global New Product Innovation Award for its FilmArray(R) Ebola Test

SALT LAKE CITY, Feb. 10, 2015 /PRNewswire/ -- BioFire Defense, LLC is proud to announce that it is the recipient of the Frost & Sullivan's 2014 Global New Product Innovation Award for its FilmArray® Ebola test. The New Product Innovation Award is given to companies that display strong overall per...

2015-02-10 15:00 1626

U.S. FDA Grants Priority Review to YONDELIS® NDA for Advanced Soft-tissue Sarcoma

MADRID, Feb. 4, 2015 /PRNewswire/ -- PharmaMar announces that the U.S. Food and Drug Administration (FDA) has granted priority review to YONDELIS® (trabectedin) New Drug Application (NDA) for the treatment of patients with advanced soft tissue sarcoma (STS), including liposarcoma and leiomyosarco...

2015-02-04 09:30 2245

MicroConstants China In-licenses Global Rights of AA98 Antibody Drug Candidates from Institute of Biophysics, Chinese Academy of Sciences

BEIJING, Jan. 30, 2015 /PRNewswire/ -- MicroConstants China Inc., announced today that it has signed a licensing agreement to gain the global rights for the development of AA98 antibody drug candidates for the treatment of various cancers, multiple sclerosis (MS), and age related macular degenera...

2015-01-30 00:52 2457

American Heart Association continues global expansion of lifesaving work

DALLAS, Jan. 27, 2015 /PRNewswire/ -- Cardiovascular disease knows no borders, and currently accounts for more than 17 million deaths per year, a figure expected to reach approximately 23 million per year by 2030. That's why the American Heart Association (AHA) is committed to building healthier ...

2015-01-27 23:00 1161

European Hantavirus Diagnostics Market Tops US Market as a Result of Higher Disease Prevalence

MOUNTAIN VIEW, Calif., Jan. 27, 2015 /PRNewswire/ -- The European Hantavirus diagnostics market is growing at a compound annual growth rate (CAGR) of 5.8 percent, outperforming the U.S. market, which registered 3.7 percent. The European market is more robust primarily due to Hantavirus' high prev...

2015-01-27 20:45 1920

Pfanstiehl Launches New cGMP-produced, Parenteral Grade Maltose for Pharmaceutical Formulations

CHICAGO, Jan. 26, 2015 /PRNewswire/ -- Pfanstiehl has announced the launch of a new high purity, low endotoxin, Maltose (USP/NF, EP, JP), manufactured in the US under strict cGMP, ICH Q7 compliant conditions.  "Maltose is a multifunctional disaccharide used to stabilize protein therapeutics, i...

2015-01-26 21:52 1339

Malaysia well positioned to grow in medical tourism, medical devices and private healthcare services, says Frost & Sullivan

KUALA LUMPUR, Malaysia, Jan. 26, 2015 /PRNewswire/ -- By 2025, total healthcare expenditure inMalaysia could exceed USD20 billion. In the next five years (2015 to 2020), it is expected to grow at a compound annual growth rate (CAGR) of 11%. While Government spending will focus on development of p...

2015-01-26 14:58 1333

European Medicines Agency Accepts Samsung Bioepis' Enbrel(R) Biosimilar Candidate, SB4, for Regulatory Review

INCHEON, South Korea, Jan. 21, 2015 /PRNewswire/ -- Samsung Bioepis Co., Ltd., today announced that the Marketing Authorization Application (MAA) for its Enbrel (etanercept) biosimilar candidate, SB4, has been validated and accepted for review by European Medicines Agency (EMA). The acceptance of...

2015-01-21 22:00 2828

Mundipharma Announces Plans to Distribute Medifoam in China

SINGAPORE, Jan. 15, 2015 /PRNewswire/ -- Mundipharma today announced its planned distribution ofMedifoam® in China starting early 2015, marking a key milestone in the company's plan to rapidly expand the innovative moist wound dressing product's reach inEast Asia and South East Asia. Medifoam® wa...

2015-01-15 10:00 2382

Polymer Chameleons Find New Applications as Research Activities Rise

MOUNTAIN VIEW, Calif., Jan. 13, 2015 /PRNewswire/ -- Polymer chameleons are poised for rapid adoption and commercialization across industries due to their unique attributes and benefits. Despite several challenges, research activities and partnerships between the research community and the indust...

2015-01-13 21:00 2078

Analysts Predict a Big Year for Healthcare in 2015

MOUNTAIN VIEW, Calif., Jan. 13, 2015 /PRNewswire/ -- WHEN: 10:00 a.m. EST on Tuesday, Jan. 27, 2015 LOCATION: Online, with Free Registration (Email Jennifer.Carson@Frost.com ) MODERATOR: Frost & Sullivan Partner and Senior Vice President of Healthcare...

2015-01-13 20:45 1453

PharmaMar Will Start a Phase III Study of PM1183 in Combination With Doxorubicin in Relapsed SCLC

MADRID, Jan. 13, 2015 /PRNewswire/ -- * The unparalleled results obtained in the Phase Ib study support the start of a head-to-head study in relapsed small-cell lung cancer (SCLC) patients that will compare the combination as second line therapy against topotecan, the only drug approved in th...

2015-01-13 09:30 1922

A World First at the Montreal Heart Institute - Discovery of a personalized therapy for cardiovascular disease

MONTREAL, Jan. 13, 2015 /PRNewswire/ -- Researchers at the Montreal Heart Institute announced today results showing that patients with cardiovascular disease and the appropriate genetic background benefit greatly from the new medication dalcetrapib, with a reduction of 39% in combined clinical ou...

2015-01-13 09:08 2281
1 ... 37383940414243 ... 47